Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: MPNST (Malignant Peripheral Nerve Sheath Tumor) Clear all
Completed Phase 1 Interventional

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

NCT01169584
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor, Ewing's Sarcoma
Interventions
Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Drug
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
2 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Jul 23, 2026, 10:13 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

NCT05275478
View directory record Official record
Conditions
Locally Advanced Solid Tumor
Interventions
TNG908
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting No phase listed Observational

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

NCT03141021
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2053
U.S. locations
9
States / cities
Tampa, Florida • Baltimore, Maryland • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

NCT00720174
View directory record Official record
Conditions
Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Malignant Adult Hemangiopericytoma, Malignant Childhood Hemangiopericytoma, Metastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions
Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 23, 2026, 10:13 AM EDT
Active, not recruiting Phase 1 Interventional

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT03618381
View directory record Official record
Conditions
Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma
Interventions
second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

NCT00474994
View directory record Official record
Conditions
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer, Sarcoma, Small Intestine Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831
View directory record Official record
Conditions
Locally Advanced Solid Tumor
Interventions
TNG462, Pembrolizumab
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Palo Alto, California • Grand Junction, Colorado • Lake Mary, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Completed No phase listed Observational

Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas

NCT01567046
View directory record Official record
Conditions
Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Neurofibrosarcoma, Childhood Synovial Sarcoma, Chordoma, Desmoid Tumor, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Recurrent Childhood Soft Tissue Sarcoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 1 Interventional

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT04897321
View directory record Official record
Conditions
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma
Interventions
Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

NCT04530487
View directory record Official record
Conditions
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide, Fludarabine Phosphate, Lapine T-Lymphocyte Immune Globulin, Melphalan, Mycophenolate Mofetil, Tacrolimus, Thiotepa
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Early Phase 1 Interventional

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

NCT06693284
View directory record Official record
Conditions
Primary Malignant Peripheral Nerve Sheath Tumors
Interventions
mirdametinib and vorinostat
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 1 Interventional

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT04222413
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Interventions
Metarrestin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Fairway, Kansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

NCT02008877
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
Interventions
ganetespib, Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 3 Interventional

Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis

NCT00091351
View directory record Official record
Conditions
Sarcoma
Interventions
conventional surgery, radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
55
States / cities
Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors

NCT00931931
View directory record Official record
Conditions
Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Soft Tissue Sarcoma, Neuroblastoma, Wilms Tumor, Malignant Peripheral Nerve Sheath Tumor, Clival Chordoma, Non-CNS Solid Tumors
Interventions
HSV1716
Biological
Lead sponsor
Timothy Cripe
Other
Eligibility
7 Years to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting No phase listed Observational

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

NCT06222203
View directory record Official record
Conditions
Neurofibromatosis 1, Nerve Sheath Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 120 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 1 Interventional

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

NCT06041516
View directory record Official record
Conditions
Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
Interventions
ADCT-701
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

NCT00304083
View directory record Official record
Conditions
Neurofibromatosis Type 1, Sarcoma
Interventions
filgrastim, doxorubicin hydrochloride, etoposide, ifosfamide, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
17
States / cities
Birmingham, Alabama • Santa Monica, California • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

NCT01154452
View directory record Official record
Conditions
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

NCT01661283
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
Interventions
everolimus, bevacizumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

NCT04465643
View directory record Official record
Conditions
Nerve Sheath Tumors
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

NCT01418001
View directory record Official record
Conditions
Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Interventions
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

NCT05985161
View directory record Official record
Conditions
Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
Interventions
Selinexor
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Months and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery

NCT00450736
View directory record Official record
Conditions
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Interventions
celecoxib, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jul 23, 2026, 10:13 AM EDT